The Ground Rules of Nonclinical Testing Are Changing
When the FDA Modernization Act 2.0 took effect in December 2022, a legal premise that had stood for some sixty years — that animal testing is mandatory for new drug approval — was struck from the statute. The follow-on discussion around Modernization Act 3.0 centers on the procedures by which alternative methods will be formally recognized, and in 2025 the FDA laid out a roadmap to phase down animal testing requirements, beginning with areas such as monoclonal antibodies. In Europe, EMA and EU-level reviews are underway, and the UK has published a phase-out roadmap. Regulatory pressure is now building on both sides of the Atlantic at once.
Korea is not outside this current. A 2023 regulatory revision established the basis for submitting non-animal and human-based test data, and validation and standardization work is progressing with KoCVAM (the Korean Center for the Validation of Alternative Methods) at its center.
The right reading matters here. What is happening is not the abolition of animal testing but a shift into a phase where animal testing alone is no longer sufficient. The center of gravity is moving toward a regime in which sponsors who cannot explain mechanism of action with supporting alternative-method data carry a heavier burden of justification during review.
Which Tests Are Being Replaced First
Local toxicity is where replacement has taken hold first. Skin irritation and corrosion, eye irritation, and skin sensitization are already internationally standardized under OECD test guidelines (the TG 431, 439, 492, and 442 series), and results from reconstructed human epidermis models or in chemico assays are routinely accepted as regulatory submission data.
Repeated-dose systemic toxicity, reproductive and developmental toxicity, and in vivo pharmacokinetics, by contrast, sit further down the queue. Organoids, organ-on-a-chip systems, and human tissue models are producing meaningful results in predicting hepatotoxicity and cardiotoxicity, but clear limits remain in reproducing systemic exposure and organ-to-organ interaction.
The deciding factor is the level of validation. Regulators look for documented reproducibility, predictive power, and a defined applicability domain for the method itself. A substantial gap still separates publication-grade data from submission-grade data.
Two Branches of Opportunity and Risk for SME Biotechs
From a developer's perspective, the clearest gain lies in early screening. Introducing cell- and organoid-based toxicity screening at the candidate stage cuts both cost and timeline significantly against animal studies while filtering out likely failures early. Whether that same data will be accepted as part of an IND submission, however, is an entirely separate question.
From a platform and CRO perspective, the growth of domestic organoid companies is opening new service contracts. Few organizations hold both GLP accreditation and method validation data, so there is a real first-mover advantage for those entering now.
The risk is equally clear: investing in equipment and platforms while domestic guidelines for a given endpoint remain unsettled, only to be asked for animal data again at the submission stage. That scenario costs both time and money twice over.
Practical Decision Criteria for Right Now
First, distinguish supporting data from primary data. Treating local toxicity endpoints with established international guidelines as primary data, and everything else as supporting data that reinforces mechanistic explanation, is the safe default at present.
Second, always go through pre-submission consultation. Use a Pre-IND meeting or MFDS pre-review to obtain written confirmation on whether a given method can substitute for a given endpoint. Verbal feedback alone is not a basis to build on.
Third, ask four questions when selecting a GLP test facility: the GLP scope covering that specific alternative method, its regulatory submission track record over the past three years, whether it holds method validation reports, and its capacity to run animal studies in parallel. These four questions will usually reveal a facility's real capability.
A Preparation Roadmap and Government Funding Links
We recommend redesigning the testing portfolio pipeline by pipeline in three stages. Stage one is tabulating the nonclinical endpoints of programs in development and sorting them into replaceable, partially replaceable, and not replaceable. Stage two runs pilot studies on the replaceable endpoints and checks correlation against existing animal study results. Stage three finalizes the submission strategy in light of pre-submission consultation outcomes.
Much of this work can be funded through government R&D. The new drug development track of the Bio and Medical Technology Development Program, support programs tied to advanced bio materials demonstration, and enterprise-led projects under SME technology development programs all allow nonclinical testing costs to be budgeted as direct expenses. Forming a consortium project with an alternative-methods platform company is another viable route.
---
KITIM supports the full path from nonclinical testing strategy through government R&D project planning to preparing materials for pre-submission consultations. If you are unsure where to begin redesigning the testing portfolio for your pipeline, please feel free to request a consultation. We will work with you to build an executable roadmap matched to your development stage and target markets.